Overview

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

Status:
Completed
Trial end date:
2015-02-02
Target enrollment:
Participant gender:
Summary
The study will evaluate the influence of hepatic insufficiency on the PK of ACP-196.
Phase:
Phase 1
Details
Lead Sponsor:
Acerta Pharma BV
Treatments:
Acalabrutinib